![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
A Phase 1 Study to Evaluate the Interaction of HCV NS5B Inhibitor MK-3682 With HCV NS3/4A Protease Inhibitor MK-5172 and HCV NS5A Inhibitor MK-8408 in Healthy Subjects
|
|
|
Reported by Jules Levin
EASL 2015 Apr 22-26 Vienna, Austria
Xiao-Jian Zhou1; Eric Sicard2; Jie Chen1; Dodie Frank1; Wei Gao3; Matthew L. Rizk3; Elizabeth G. Rhee3; Joan R. Butterton3; John Sullivan-Bolyai1
1Idenix Pharmaceuticals Inc., a wholly owned subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA; 2Algorithme Pharma, Montreal, Quebec, Canada; 3Merck & Co., Inc., Kenilworth, NJ, USA
![EASL1.gif](../images/042315/042315-3/EASL1.gif)
![EASL2.gif](../images/042315/042315-3/EASL2.gif)
![EASL3.gif](../images/042315/042315-3/EASL3.gif)
![EASL4.gif](../images/042315/042315-3/EASL4.gif)
![EASL5.gif](../images/042315/042315-3/EASL5.gif)
![EASL6.gif](../images/042315/042315-3/EASL6.gif)
![EASL7.gif](../images/042315/042315-3/EASL7.gif)
![EASL8.gif](../images/042315/042315-3/EASL8.gif)
![EASL9.gif](../images/042315/042315-3/EASL9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|